156 related articles for article (PubMed ID: 37345121)
41. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide.
Poteska R; Rahbar K; Semjonow A; Schrader AJ; Boegemann M; Schlack K
BMC Cancer; 2022 Apr; 22(1):375. PubMed ID: 35395766
[TBL] [Abstract][Full Text] [Related]
42. Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
Alva A; Nordquist L; Daignault S; George S; Ramos J; Albany C; Isharwal S; McDonald M; Campbell G; Danchaivijitr P; Yentz S; Anand A; Yu EY
Prostate; 2017 Apr; 77(5):479-488. PubMed ID: 27990667
[TBL] [Abstract][Full Text] [Related]
43. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan.
Yao SF; Huang WJ; Wei TC; Wang YF; Lin KH; Hu LH; Ting CH; Lee TH; Yeh SH; Peng NJ
J Chin Med Assoc; 2024 May; ():. PubMed ID: 38771079
[TBL] [Abstract][Full Text] [Related]
44. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
[No Abstract] [Full Text] [Related]
45. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
46. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
[TBL] [Abstract][Full Text] [Related]
47.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
48. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Miyoshi Y; Tsutsumi S; Yasui M; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
World J Urol; 2021 Sep; 39(9):3323-3328. PubMed ID: 33644830
[TBL] [Abstract][Full Text] [Related]
49. Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice.
Prelaj A; Rebuzzi SE; Buzzacchino F; Pozzi C; Ferrara C; Frantellizzi V; Follacchio GA; Civitelli L; De Vincentis G; Tomao S; Bianco V
Oncol Lett; 2019 Feb; 17(2):1467-1476. PubMed ID: 30675201
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
51. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
52. Clinical Significance of the Highest Regional Bone Scan Index in Patients with Metastatic Castration-Resistant Prostate Cancer.
Nakai Y; Iemura Y; Miyasaka T; Hori S; Miyake M; Marugami N; Fujimoto K; Tanaka N
Nucl Med Mol Imaging; 2022 Oct; 56(5):221-227. PubMed ID: 36310836
[TBL] [Abstract][Full Text] [Related]
53. Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
Tong T; Lei H; Guan Y; Yang X; Liao G; Li Y; Jiang D; Pang J
Front Oncol; 2020; 10():586192. PubMed ID: 33330067
[TBL] [Abstract][Full Text] [Related]
54.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
55. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
56. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
57. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
Anido-Herranz U; Fernandez-Calvo O; Ruiz-Bañobre J; Martinez-Breijo S; Fernandez-Nuñez N; Nogareda-Seoane Z; Garrido-Pumar M; Casas-Nebra J; Muñiz-Garcia G; Portela-Pereira P; Gomez-Caamaño A; Perez-Fentes DA; Santome-Couto L; Lázaro M; Molina-Diaz A; Medina-Colmenero A; Vazquez-Estevez S
Front Oncol; 2024; 14():1385466. PubMed ID: 38774416
[TBL] [Abstract][Full Text] [Related]
58. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
59.
Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
[TBL] [Abstract][Full Text] [Related]
60.
Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
